The MErCuRIC team of researchers assembled for the Month 60 plenary meeting on November 8th and 9th in Italy. On the 8th the group was met at the Candiolo Cancer Institute (IRCCS) and on the 9th at the Molecular Biotechnology Center of the University of Torino (UNITO). After an overview and report on the project progress […]
Northern Ireland Cancer Research Consumer Forum (NICRCF) member, Ed Goodall, was elected in 2018 to the Patient Advisory Group of the EuropaColon organisation which incorporates researchers and healthcare professionals from nearly 40 countries. The EuropaColon Patient Advisory Group held their most recent meeting in October 2018 in Munich in conjunction with that of the European Society […]
Cancer researchers at Queen’s University Belfast and the University of Leeds, as part of a pan-European partnership, called the European Cancer Concord (ECC) won the prestigious 2018 European Health Award. MErCuRIC PI Professor Mark Lawler, Chair in Translational Cancer Research at Queen’s University Belfast and Vice President of ECC, received the award on October 3, […]
Partners Dr Vlad Popovici and Anna Pečinková, Faculty of Informatics, Research Centre for Toxic Compounds in the Environment (RECETOX), Masarykova Univerzita presented MErCuRIC research, “Cross-platform gene expression signature for microsatellite instability in colon and gastric cancers” at the European Conference on Computational Biology (ECCB) 2018 in Athens, Greece. The conference was held September 8- 12, 2018. ECCB […]
On November 16, 2018, MErCuRIC PI, Professor Richard Wilson of Queen’s University Belfast will present “A phase I dose escalation multi-centre study crizotinib (MET inhibitor) in patients with advanced solid tumours” during a “Molecular Targeted Agents” session of the EORTC-NCI-AACR Symposium. The meeting will take place on 13-16 November 2018 in The Convention Centre Dublin, in the Republic of […]
New findings emerging from the research team at Queen’s University Belfast have identified a cellular process which can be exploited in order to kill BRAF mutant colon cancer cells, a particularly aggressive subgroup of colon cancers. These cancers are not only extremely aggressive but they do not respond well to conventional cancer treatments. The QUB […]
A new MErCuRIC study from Prof Alberto Bardelli and the team at the University of Torino has just been published. The article entitled “Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer” was published on 9 July 2018 in Cancer Cell. Congratulations to the entire research team: Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Andrea Sartore-Bianchi, Benedetta […]
In celebration of International Clinical Trials Day on 18 May 2018, an exhibition showcased cancer clinical studies in the Northern Ireland Cancer Centre. MErCuRIC and all open clinical studies where there was local leadership were promoted. Patient representatives Margaret Grayson and Dr Edward Goodall were part of the team from the Northern Ireland Cancer Research Consumer Forum (NICRCF), […]
Esther Harding (EH) spoke to Ruth Boyd* (RB) in the Northern Ireland Cancer Centre, May 2018. Esther is 69 years of age, lives in Northern Ireland and is married with 3 sons, 3 daughters-in-law and 7 grandchildren. RB: Hello Esther, thank you for speaking to us about the MErCuRIC study. How long have you been […]
The MErCuRIC three-minute explainer video was launched on 21 May 2018. Please watch, utilize and share it!
MErCuRIC is funded by the European Community’s Framework Programme Seven (FP7) under contract #602901. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.
